HOW TO REDUCE GASTROINTESTINAL BLEEDING RISK ON ANTICOAGULATION THERAPY IN NON-VALVULAR ATRIAL FIBRILLATION?
https://doi.org/10.15829/1560-4071-2017-10-124-132
Abstract
Atrial fibrillation (AF) is a significant risk factor for stroke and systemic embolism. For prevention of these complications, most AF patients are indicated to take anticoagulants, that reduce the risk cardioembolic strokes, but increase the risk of bleedings, and the most prevalent are gastrointestinal (GIB).
Aim. To assess the rate of pathological changes in esophagus, stomach and duodenum, predisposing for GID, in AF patient with higher risk of stroke and absolute indications for anticoagulation therapy.
Material and methods. The analysis done, of case histories of hospitalized patients in the therapeutical university clinics, in the year 2016; of those — 263 with non-valvular AF. Among 222 patients with AF and higher risk of stroke, who had indications for anticoagulants, 103 underwent screening fibroesophagogastroduodenoscopy (FEGDS).
Results. The FEGDS, performed in 103 patients with non-valvular AF and high risk of stroke, in 45,6% revealed diseases predisposing to GIB, including esophageal cancer — 1 (2,1%), gastric ulcer — 4 (8,5%), duodenal ulcer — 2 (4,3%), erosive esophagitis and reflux disease — 5 (10,6%), varicose veins of esophagus — 4 (8,5%), erosive gastritis — 31 (66,0%) and erosive duodenitis — 3 (6,4%). Combination of diseases was found in 10 (21,3%) patients.
Conclusion. Patients with non-valvular AF and high stroke risk, before starting therapy with anticoagulants, it is aimworthy to perform FEGDS for on-time screening for esophageal, gastric, duodenal pathologies predisposing to GIB.
About the Authors
E. I. Baranova
I.P. Pavlov First Saint-Petersburg State Medical University; Federal Almazov North-West Medical Research Centre of the Ministry of Health
Russian Federation
Russian Federation
А. G. Filatova
I.P. Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
V. A. Ionin
I.P. Pavlov First Saint-Petersburg State Medical University
Russian Federation
Russian Federation
References
1. Yoshida T, Fujii T, Uchino S, Takinami M. Epidemiology, prevention, and treatment of new-onset atrial fibrillation in critically ill: a systematic review. J. Intensive Care, 2015; 3 (11): 1-11.
2. 2016 ESC guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur. Heart J, 2016; DOI:10.1093/eurheartj/ehw210.
3. Lip GYH, Clemens A, Noack H, et al. Patient outcomes using European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost. 2014; 111 (5): 933-42.
4. Raiman L, Antbring H, Abu-Sitta A, Al-Refaie FN. A district general hospital experience of patients receiving apixaban, dabigatran, rivaroxaban or warfarin for anticoagulation. Blood. 2016; 128: 4733.
5. Guerrouij M, Uppal CS, Alklabi A, Douketis JD. The clinical impact of bleeding during oral anticoagulant therapy: assessment of morbidity, mortality and post-bleed anticoagulant management. J Thromb Thrombolysis 2011; 31: 419-23.
6. Marmo R, Koch M, Cipolletta L, et al. Italian registry on upper gastrointestinal bleeding. Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the Italian PNED score and prospective comparison with the Rockall score. Am J Gastroenterol. 2010; 105: 1284-91.
7. Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol. 2016; 111: 459-74.
8. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
9. Roskell NS, Samuel M, Noack H, Monz BU. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace. 2013; 15: 787-97.
10. Lip GYH, Lane DA. Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus. European Heart J. 2015; 36: 3265-7.
11. Cheung K-S, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J Gastroenterol. 2017; 23 (11): 1954-63.
12. Di Minno MND, Ambrosino P, Di Minno A, et al. The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systemic review and meta-analysis of the literature. Ann Med. 2017; 49 (4): 329-42.
13. Graham D, Reichman ME, Wernecke M, et al. Stroke, bleeding and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for non-valvular atrial fibrillation. JAMA Intern Med. 2016; 176 (11): 1662-71.
14. Bai Y, Deng H, Shantsila A, Lip GYH. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation. Stroke. 2017; 48: 970-6.
15. Mazurek M, Lip GYH. Editorials. Gastroenterology. 2017; 152: 932-4.
16. Asiimwe A, Li JJ, Weerakkody G, et al. Diagnoses of gastrointestinal cancers after gastrointestinal bleeding in patients receiving clopidogrel or warfarin. Curr Drug Saf. 2013; 8: 261-9.
17. Clemens A, Stack A, Noack H, et al. Anticoagulant-related gastrointestinal bleeding — could this facilitate early detection of benign or malignant gastrointestinal lesions? Annals of medicine 2014; DOI: 10.3109/07853890.2014.952327.
18. Flack KF, Desai J, Kolb JM, et al. Major gastrointestinal bleeding often is caused by occult malignancy in patients receiving warfarin or dabigatran to prevent stroke and systemic symbolism from atrial fibrillation. Clinical Gastroenterol Hepatol. 2017; 15: 682-90.
19. Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012; 107: 838-47.
20. Norton SA, Armstrong CP. Lower gastrointestinal bleeding during anticoagulant therapy: a life-saving complication? Ann R Coll Surg Engl.1997; 79: 38-9.
21. Desai JC, Chatterjee P, Friedman K, Aisenberg J. Incidence and clinical presentation of gastrointestinal bleeding in atrial fibrillation patients taking direct oral anticoagulants. Am J Gastroenterol. 2016; 3, suppl.: 13-21.
22. Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology 2015; 149: 586-95.
23. LaHaye S, Regpala S, Lacombe S, et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost. 2014; 111: 456-73.
Review
For citations:
Baranova E.I., Filatova А.G., Ionin V.A. HOW TO REDUCE GASTROINTESTINAL BLEEDING RISK ON ANTICOAGULATION THERAPY IN NON-VALVULAR ATRIAL FIBRILLATION? Russian Journal of Cardiology. 2017;(10):124-132. (In Russ.) https://doi.org/10.15829/1560-4071-2017-10-124-132
Views:
953
Email this article 